Background: Cardiac rehabilitation (CR) improves the symptoms, exercise capacity and quality of life of chronic heart failure (CHF) patients. Its effects on new plasma biomarkers of prognostic importance are unknown. The present study aimed at analysing the effects of a structured CR programme on plasma cardiac biomarkers in a large population of patients with CHF and reduced left ventricular ejection fraction (LVEF). Methods: We enrolled 107 consecutive CHF patients with LVEF 45% in an ambulatory CR programme. Peak VO 2 and plasma levels of Galectin-3, mid-regional proANP (MR-proADM), soluble suppressor of tumorigenicity 2 (sST2) and midregional pro-adrenomedullin (MR-proANP) were assessed at inclusion and at the end of CR. Twenty-four unenrolled patients were managed with standard medical care and evaluated over the same period (no-CR group). Results: Galectin-3, sST2, MR-proADM and MR-proANP plasma levels decreased after CR, with respective median reductions of 6.3% for Galectin 3 (p < 0.001), 7.4% for sST2 (p ¼ 0.036), 6.4% for MR-proADM (p ¼ 0.001) and 16% for MR-proANP (p < 0.001). MR-proADM was negatively correlated with peak VO 2 (r ¼ À0.529, 95% confidence interval [CI] À0.654 to À0.375, p < 0.001), and so were their relative variations along the course of CR (r ¼ À0.357, 95% CI -0.518 to À0.172, p < 0.001). No change occurred in terms of biomarkers in the no-CR group. Conclusions: Plasma cardiac biomarkers such as Galectin-3, MR-proADM, sST2 and MR-proANP all decreased after CR in CHF patients, suggesting an overall improvement in the neuro-hormonal profile.
Introduction
Chronic heart failure (CHF) is a frequent disease with negative outcomes that affects 1-2% of the adult population in developed countries. 1 Alterations of the neuro-hormonal systems play important roles in its pathophysiology and represent a main focus for the medical treatment. Indeed, over the past two decades, treatments aiming at mitigating the deleterious effects of the renin-angiotensin-aldosterone and the sympathetic systems, along with the development of cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators, markedly improved the survival of patients with CHF. 2 More recently, an emphasis has been given to cardiac rehabilitation (CR) in patients with CHF and left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] < 35%), which involves physical training on top of medical treatment and device implantation. 3 CR dramatically improves the symptoms, exercise capacity and quality of life of CHF patients, 4 and physical training is a class 1, grade A recommendation in international guidelines for the management of these patients. 1, 5 From a pathophysiological standpoint, training improves peripheral vasodilation and muscle strength, decreases inflammation and appears to slow the progressive remodelling of the left ventricle (LV). [6] [7] [8] [9] Taken together, these beneficial effects tend to improve the outcomes of CHF patients, although long-term physical exercise was proven to be difficult to sustain outside of supervised programmes. 3, 10 Cardiac plasma biomarkers, mostly B-type natriuretic paptide (BNP) and cardiac troponin, are currently used for the diagnosis and prognosis of patients with acute decompensated heart failure (ADHF) or CHF. The effect of medical therapy on these markers has been studied in recent years, 9, 11, 12 and a decrease in cardiac biomarkers has often been associated with an improvement in outcome. [13] [14] [15] More recently, new biomarkers have been introduced in order to better reflect the pathophysiological alterations that occur in heart failure (HF). These new biomarkers include: (i) Galectin-3 (Gal-3), which is involved in cardiac inflammation and fibrosis 16 and is strongly associated with HF development, severity 17 and prognosis 18 ; (ii) soluble suppressor of tumorigenicity 2 (sST2), which is involved in cardiac fibrosis and hypertrophy 19 and has been associated with cardiac fibrosis, ventricular remodelling and dysfunction and negative cardiovascular prognosis 20 in ADHF 21 and CHF patients 22 and is predictive of sudden death 23 ; (iii) mid-regional pro-ANP (MR-proANP), which reflects atrial overload and has been associated with poor prognosis in ADHF 24 ; and (iv) mid-regional pro-adrenomedullin (MR-proADM), a hypotensive and natriuretic hormone that has a prognostic value in ADHF 25 and has been associated with New York Heart Association (NYHA) class and 1-year mortality in CHF. 26 While CR was shown to decrease the plasma levels of classical biomarkers such as BNP, troponin or norepinephrine, 27 ,28 the effects of CR on the aforementioned new biomarkers are still unknown. The present study therefore aimed at analysing the effects of a structured and supervised CR programme on the plasma levels of classical and new biomarkers in a large population of CHF patients with LV systolic dysfunction, in order to better understand the pathophysiological pathways involved in the beneficial effects of CR.
Method
This study was approved by a local ethic committee and written consent was obtained from all patients. This study using human samples was performed according to the current revision of the Helsinki Declaration and registered at ClinicalTrials.gov under the NCT0137 4880 identifier.
Study population
The cohort consisted of 107 clinically stable, consecutive CHF patients who were enrolled from September 2010 to September 2013 in the outpatient CR centre of Lariboisie`re Hospital (Paris). All patients presented with LVEF 45% and NYHA functional class II-IV and were eligible for CR. We excluded patients with non-cardiovascular causes of exercise limitation and those with cardiovascular causes of exercise limitations: primary valve disease, congenital heart disease, active myocarditis, hypertrophic or restrictive cardiomyopathy, acute coronary syndrome or acute HF decompensation or planned coronary revascularisation or cardiac surgery. We also enrolled 24 patients with clinically stable CHF who could not attend CR for personal (distance or refusal) or clinical (CR already performed, limitations or contraindications for CR) reasons during the same period as the control group (no-CR group). These patients were followed in the HF outpatient centre of Lariboisie`re Hospital.
CR patients were evaluated at inclusion by a cardiologist and were subjected to echocardiography, blood sampling and a cardiopulmonary exercise test (CPET). The same evaluation was repeated at the end of the CR programme, 4-6 months later. No-CR patients were evaluated 4-6 months apart in a similar fashion, except they were not subjected to CPET.
Echocardiography
M-mode, 2D images and flow and tissue Doppler recordings were obtained for all patients by transthoracic echocardiography (iE 33, Philips Healthcare, Suresnes, France, or Vivid 7, GE Healthcare, Horten, Norway). The 2D imaging was performed in parasternal longand short-axis views and apical two-and four-chamber views. LV systolic and diastolic volumes and LVEF were derived from biplane apical (two-and four-chamber) views with a modified Simpson's rule algorithm.
Cardiopulmonary exercise test
Physical exercise was performed on a bicycle with 10-W/minute workload increments until exhaustion (with a peak respiratory exchange ratio always > 1.0). VO 2 , peak VO 2 and CO 2 production and ventilation were measured at each breath. The ventilatory anaerobic threshold (VAT) was measured by classical methods: the V-slope method, using the ventilatory equivalents for O 2 and CO 2 and that using the endtidal pressures of O 2 and CO 2 .
CR programme
The CR programme consisted of 40 sessions overall of supervised training, twice a week over a period of 4-6 months. Endurance training was performed on bicycle, treadmill or rowers at a workload corresponding to the VAT as determined after the reference CPET. However, the intensity of the programme was tailored to each patient according to their response and tolerance to physical exercise. For the most severe patients, a muscle reinforcement programme was implemented at the beginning and in parallel to the CR programme. After 20 sessions of CR and muscle reinforcement, a new CPET was performed and the training level was adapted if no or even only a mild improvement in exercise capacity was observed. Patients were also followed by a dietician and subjected to therapeutic education.
Biomarker analysis
Venous blood samples were collected in tubes containing ethylenediaminetetraacetic acid (EDTA). Blood samples were immediately centrifuged at 3500 rpm for 15 minutes at 4 C. BNP (ARCHITECT BNP assay, Abbott Laboratories, Abbott Park, IL, USA) plasma levels were immediately measured; the remaining plasma samples were immediately stored at À80 C until further use. The following biomarkers were assessed: MR-proANP (BÁRÁAÁHÁMÁS MR-proANP KRYPTOR, Thermo Fisher Scientific, Waltham, MA, USA), MR-proADM (BÁRÁAÁHÁMÁS MR-proADM KRYPTOR, Thermo Fisher Scientific), Gal-3 (ARCHITECT Galectin-3 assay, Abbott Laboratories) and sST2 (Test Presage ST2, Critical Diagnostics, San Diego, CA, USA). Plasma creatinine levels were also measured (ARCHITECT creatinine assay, Abbott Laboratories). All measurements was performed in the in-hospital department of biochemistry; experimenters were blinded to clinical data. Reference change value were: sST2 ¼ 42.9%, 29 MR-proADM ¼ 10.3%, Gal-3 ¼ 17.3% and MR-proANP ¼ 22.4%.
Statistical analysis
Data are expressed as mean AE SD, median (interquartile range) or number (%) as appropriate. Variables were tested using Student t-tests, Wilcoxon rank-sum tests or Fisher exact tests as appropriate. Paired data were analysed using paired Wilcoxon rank-sum tests. Relationships between variables were assessed using Spearman correlation coefficients (r). Outliers were excluded from the analysis using Grubbs tests. A twosided p-value 0 .05 was considered statistically significant. Statistical analyses were performed with the MedCalc software (Mariakerke, Belgium).
Results

Baseline characteristics
We enrolled 107 consecutive patients in our CR programme and 24 patients in the no-CR group. The two groups were similar for all parameters, except patients in the CR group were younger and had a higher BNP level than those in the no-CR group (Table 1) . Overall, 85% of the study population were male with severe LV dysfunction; ischaemic cardiomyopathy represented half of the aetiologies. Most patients received an inhibitor of the renin-angiotensin-aldosterone system and a b-blocker; approximately half of them were also treated with a mineralocorticoid receptor antagonist. The mean duration of the CR programme and the interval between examinations in the no-CR group were approximately 4 months in both groups (Table 1) .
CR programme effectiveness
CR effectiveness was assessed by comparing various parameters before and after CR. Peak VO 2 significantly increased from 17.8 mL/kg/minute (14.0-21.9 mL/kg/ minute) to 21 mL/kg/minute (16.8-25.2 mL/kg/minute) (p < 0.001), with a 14.5% median increase. NYHA functional class assessed before and after the CR programme in the 107 patients also improved (p < 0.0001), with 57 (54%) of the patients being downgraded. BNP plasma levels decreased by twofold (46% median decrease) from 276 pg/mL (155-755 pg/mL) to 129 pg/ mL (67-322 pg/mL) (p < 0.001, n ¼ 102).
Effect of CR on biomarkers
Overall, Gal-3, sST2, MR-proADM, and MR-proANP plasma levels decreased after the CR programme: the Gal-3 median decreased by 6.3% from 18.4 ng/mL (14.5-22.1 ng/mL) to 17.5 ng/mL (14.0-20.4 ng/mL) (p < 0.0001, n ¼ 107, Figure 1a) ; the sST2 median decreased by 7.4% from 36.7 ng/mL (28.1-49.7 ng/mL) to 34.6 ng/mL (26.5-48.2 ng/mL) (p ¼ 0.035, n ¼ 97, Figure 1b There was no change in any biomarker value in the no-CR group (Supplementary Table 1 ).
Relationship between biomarkers and peak VO 2
To see if any biomarker change could predict changes in exercise capacity with training, relationships between peak VO 2 and biomarkers before and after CR were studied and are shown in Table 2 . The strongest correlation we found with peak VO 2 involved MR-proADM. We illustrate in Figure 2 the correlation between the relative variations in peak VO 2 and the relative variations in MR-proADM plasma levels along the course of the CR programme (Spearman's coefficient rank correlation -0.357, 95% confidence interval [CI] -0.518 to -0.172, p < 0.01, n ¼ 99).
Evolution of biomarkers according to benefit from CR
In order to determine whether the biomarkers tested could help with identifying patients who benefited the most from CR, we divided the CR group across the median increase in the variation of peak VO 2 (Var[PVO 2 ]) before and after CR (14.5%), with patients with a peak VO 2 variation ! 14.5% being considered to be the best responders. These two subgroups were similar in terms of demographic characteristics, Table 2) . Biomarkers were also similar in both subgroups, except for BNP plasma levels, which were higher in the Var(PVO 2 ) ! 14.5% subgroup (457 pg/mL [160-1048 pg/mL]) than in the Var(PVO 2 ) < 14.5% subgroup (235 pg/mL [114-487 pg/mL]; p ¼ 0.024). While BNP plasma levels decreased in both subgroups (Table 3) , this decrease was more pronounced in the Var(PVO 2 ) ! 14.5% subgroup (Table 4) . For all of the other biomarkers tested, plasma levels decreased only in the subgroup that benefited the most from CR (Var[PVO 2 ] ! 14.5%), with their levels remaining similar before and after CR in the Var(PVO 2 ) < 14.5% subgroup (Table 3) . Consequently, the variation of the plasma levels of these markers was higher in the Var(PVO 2 ) ! 14.5% subgroup, with the exception of sST2, the variation of which was similar between the two subgroups ( Table 4) .
Discussion
This study is the first to evaluate the effects of CR on novel plasma biomarkers in patients with CHF. The present study indicated that Gal-3, sST2, MRproANP and MR-proADM decreased after the CR programme in patients with CHF. More importantly, these results show that these biomarkers only decreased in patients who benefited the most from CR, suggesting the overall improvement of the neuro-hormonal profile as being part of their better outcome, and highlighting the beneficial effect of physical training alone. Finally, these four biomarkers outperformed BNP at identifying the patients who benefited the most from CR, laying the foundation for effective biomarker-guided CR.
We previously showed that improvement in peak VO 2 should be considered as the main target of CR, since it is strongly associated with good prognosis in CHF patients with LVEF < 45%. 30 In the present study, the CR programme that the patients were subjected to was successful overall, since the 14.5% increase in peak VO 2 is in line with previous reports. 31, 32 The efficiency of the CR programme was associated with a decrease in plasma BNP, which was shown to be of prognostic value. 13, 33 Notably, this decrease in plasma BNP (-46%) was higher than previously described (-34% 28 and -28% 31 ), but the higher severity of the LV dysfunction in our population at baseline (30% vs. 35%) may account for such a difference. However, these results contrast with those published from the HF-ACTION trial, which found a modest effect of physical exercise on classical cardiac biomarkers, most likely due to the very modest effect of CR on exercise capacity (4% increase only in peak VO 2 at 3 months) in HF-ACTION, 27 which was not in line with what has been found in meta-analyses. 34 Nevertheless, we observed a decrease in BNP regardless of the variation in peak VO 2 , suggesting that BNP variations may be more sensitive to CR and less dependent on peak VO 2 variations than the other biomarkers. Therefore, BNP could not identify those who benefitted the most from CR using variations in peak VO 2 as an indicator of CR efficiency. Importantly, MR-proANP was only decreased in patients who benefited the most from CR, suggesting that CR reduced the ventricular load in all patients, and that those who benefitted the most from CR also experienced a decrease in atrial load.
The inability of BNP to clearly identify the patients who benefitted the most from CR prompted us to evaluate other biomarkers associated with other pathophysiological aspects of HF, such as cardiac fibrosis, inflammation and remodelling. All three of the biomarkers tested, namely Gal-3, sST2 and MRproADM, decreased moderately (5-8%) in the overall population, but they only did so in the population that benefitted the most from CR. Firstly, CR is the first therapeutic intervention to date that is accompanied by a decrease in Gal-3 plasma level. Since Gal-3 has been shown not to be affected by medication [21] [22] [23] 30 or CRT devices, 35 this decrease in Gal-3 is most likely a direct effect of physical exercise. Secondly, in the CR-responsive population, sST2 levels fell to below the 35 ng/mL threshold, which has been found to be associated with a lower 1-year mortality in CHF patients. 21 Finally, MR-proADM was also decreased in CR best-responders, but contrary to the other biomarkers tested, MR-proADM was best correlated with peak VO 2 . Overall, these data strongly suggest that the benefit of CR is accompanied by an overall normalisation of the neuro-hormonal response and a relief of inflammation/fibrosis processes. It is worth mentioning that the variations observed for sST2 and Gal-3 fell within the reference change values, suggesting that the variations we observed may reflect intra-individual variations rather than positive effects of CR. However, the differences were strongly significant, which highlights the importance of further studies regarding these biomarkers.
This study suffers from several limitations. Firstly, this study was monocentric. However, the monocentric Figure 2 . Relationship between the variations before and after cardiac rehabilitation of MR-proADM and peak VO 2 in chronic heart failure patients. MR-proADM: mid-regional pro-adrenomedullin.
characteristic of the study allowed us to provide the patients with comparable and effective CR interventions, which may not have been the case in the context of a multicentric study (e.g. HF-ACTION 27 ). Secondly, this study was not randomised. However, we considered it to be non-ethical not to propose CR to all eligible patients, since the results of the HF-ACTION trial set CR as a first-line treatment in CHF; in addition, the fact that no change was observed in our control group that was followed in the same centre further strengthens our findings. Thirdly, the study population was limited. However, our results set CR as a major therapeutic strategy for homogeneously decreasing a large number of biomarkers that are suggestive of poor outcomes in these patients; in fact, we are unaware of any drug or device to have shown such an effect. Moreover, the results we obtained clearly show that new biomarkers can be used to establish the efficiency of CR and to help guide this intervention. Further studies are required in order to confirm the performance of the biomarkers we selected in larger and multicentric populations.
In conclusion, CR was shown to decrease plasma biomarkers in CHF patients. We also showed that only the patients who benefitted the most from the CR programme exhibited decreases in plasma levels of Gal-3, sST2, MR-proANP and MR-proADM, which suggest systemic and cardiac improvement. From a pathophysiological standpoint, these results strongly suggest that an effective CR programme is accompanied by a decrease in constraints (MR-proANP and BNP), inflammation and/or fibrosis (Gal-3 and sST2), as well as an improvement in endothelial-derived vasodilation (MR-proADM), which explains the benefits on symptoms, exercise capacity and outcomes. From a clinical standpoint, these biomarkers improved current biomarker follow-up in CR, since BNP was found to be decreased in all patients, regardless of the benefit of CR.
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